Management Guidelines for Mucopolysaccharidosis VI
Roberto Giugliani, Paul Harmatz, James Edmond Wraith · PEDIATRICS · 2007
Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) is a lysosomal storage disease that is characterized by systemic clinical manifestations and significant functional impairment. Diagnosis and management are often challenging because of the considerable variability in symptom presentation and rate of progression. The optimal standard of care should be based on evidence from randomized, controlled trials, meta-analyses, systematic reviews, and expert opinion. In support of this goal, comprehensive management guidelines have been drafted by an international group of experts in the management of patients with mucopolysaccharidosis VI. The guidelines provide a detailed outline of disease manifestations by body system, recommendations for regular assessments, and an overview of current treatment options.
Cited by 253 works. doi:10.1542/peds.2006-2184
Authors
References
- The Metabolic and Molecular Bases of Inherited Disease
- ATS Statement: Guidelines for the Six-Minute Walk Test
- Prevalence of Lysosomal Storage Disorders
- The frequency of lysosomal storage diseases in The Netherlands
- Cord-Blood Transplants from Unrelated Donors in Patients with Hurler's Syndrome
- Human Gene Mutation Database
- Bone-Marrow Transplantation in the Maroteaux–Lamy Syndrome (Mucopolysaccharidosis Type VI)
- An update on the frequency of mucopolysaccharide syndromes in British Columbia
- Cumulative incidence rates of the mucopolysaccharidoses in Germany
- Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study